No posts to display
Top News
JW Pharmaceutical Files for South Korea Phase 3 Trial of Once-Every-Two-Weeks...
JW Pharmaceutical is seeking to advance Bofanglutide into a South Korean Phase 3 trial, aiming to halve the dosing frequency of GLP-1 obesity treatments from once weekly to once every two weeks.
- Our Sponsors Ad -